Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells

Cytotherapy

Volumn 18, Issue 7, 2016, Pages 893-901

  Stroncek, David F ^a   Ren, Jiaqiang ^a   Lee, Daniel W ^b   Tran, Minh ^a   Frodigh, Sue Ellen ^a   Sabatino, Marianna ^a   Khuu, Hanh ^a   Merchant, Melinda S ^b   Mackall, Crystal L ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

acute lymphocytic leukemia; adoptive cellular therapy; CD19; chimeric antigen receptor T cells; GD2; osteosarcoma

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GANGLIOSIDE GD2; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADHERENT CELL; ADOPTIVE IMMUNOTHERAPY; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CELL COUNT; CELL EXPANSION; CELL THERAPY; CLINICAL OUTCOME; ENRICHMENT CULTURE; GRANULOCYTE; HUMAN; HUMAN CELL; LEUKOCYTE CULTURE; NEUROBLASTOMA; OPEN STUDY; OSTEOSARCOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; T CELL LYMPHOMA; T LYMPHOCYTE; CELL PROLIFERATION; CHILD; CLINICAL TRIAL; CYTOLOGY; GENETIC TRANSDUCTION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MONOCYTE; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; YOUNG ADULT;

ANTIGENS, CD19; CELL PROLIFERATION; CHILD; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; MONOCYTES; MYELOID CELLS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; YOUNG ADULT;

EID: 84988943579     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2016.04.003     Document Type: Article

References (21)

1. [1] Kochenderfer, JN, Wilson, WH, Janik, JE, Dudley, ME, Stetler-Stevenson, M, Feldman, SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116 (2010), 4099–4102.
2. [2] Kochenderfer, JN, Dudley, ME, Feldman, SA, Wilson, WH, Spaner, DE, Maric, I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119 (2012), 2709–2720.
3. [3] Kochenderfer, JN, Dudley, ME, Carpenter, RO, Kassim, SH, Rose, JJ, Telford, WG, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122 (2013), 4129–4139.
4. [4] Lee, DW, Kochenderfer, JN, Stetler-Stevenson, M, Cui, YK, Delbrook, C, Feldman, SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385 (2015), 517–528.
5. [5] Porter, DL, Levine, BL, Kalos, M, Bagg, A, June, CH, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365 (2011), 725–733.
6. [6] Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368 (2013), 1509–1518.
7. [7] Porter, DL, Hwang, WT, Frey, NV, Lacey, SF, Shaw, PA, Loren, AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med, 7, 2015, 303ra139.
8. [8] Garfall, AL, Maus, MV, Hwang, WT, Lacey, SF, Mahnke, YD, Melenhorst, JJ, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med 373 (2015), 1040–1047.
9. [9] Tumaini, B, Lee, DW, Lin, T, Castiello, L, Stroncek, DF, Mackall, C, et al. Simplified process for the production of anti-CD19-CAR-engineered T cells. Cytotherapy 15 (2013), 1406–1415.
10. [10] Fry, TJ, Mackall, CL, T-cell adoptive immunotherapy for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2013 (2013), 348–353.
11. [11] De, VK, Van, VE, Lahmar, Q, Geeraerts, X, De, BE, Menu, E, et al. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front Oncol, 4, 2014, 349.
12. [12] Yazdani, Y, Mohammadnia-Afrouzi, M, Yousefi, M, Anvari, E, Ghalamfarsa, G, Hasannia, H, et al. Myeloid-derived suppressor cells in B cell malignancies. Tumour Biol 36 (2015), 7339–7353.
13. [13] Jiang, J, Guo, W, Liang, X, Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients. Hum Immunol 75 (2014), 1128–1137.
14. [14] Zhang, H, Maric, I, DiPrima, MJ, Khan, J, Orentas, RJ, Kaplan, RN, et al. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood 122 (2013), 1105–1113.
15. [15] Solito, S, Marigo, I, Pinton, L, Damuzzo, V, Mandruzzato, S, Bronte, V, Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 1319 (2014), 47–65.
16. [16] Stroncek, DF, Fellowes, V, Pham, C, Khuu, H, Fowler, DH, Wood, LV, et al. Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies. J Transl Med, 12, 2014, 241.
17. [17] Powell, DJ Jr, Brennan, AL, Zheng, Z, Huynh, H, Cotte, J, Levine, BL, Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program. Cytotherapy 11 (2009), 923–935.
18. [18] Mossoba, ME, Halverson, DC, Kurlander, R, Schuver, BB, Carpenter, A, Hansen, B, et al. High-dose sirolimus and immune-selective pentostatin plus cyclophosphamide conditioning yields stable mixed chimerism and insufficient graft-versus-tumor responses. Clin Cancer Res 21 (2015), 4312–4320.
19. [19] Long, AH, Haso, WM, Shern, JF, Wanhainen, KM, Murgai, M, Ingaramo, M, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21 (2015), 581–590.
20. [20] Zheng, Z, Chinnasamy, N, Morgan, RA, Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. J Transl Med, 10, 2012, 29.
21. [21] Jena, B, Maiti, S, Huls, H, Singh, H, Lee, DA, Champlin, RE, et al. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS ONE, 8, 2013, e57838.